ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Exelixis Initiates Phase 1/2 Trial Of XL184 In Patients With Non-Small Cell Lung Cancer
Exelixis,
Inc. (Nasdaq: EXEL) announced that it has initiated a phase 1/2 trial
of XL184 in patients with non-small cell lung cancer (NSCLC) who have had
progressive disease while on a regimen containing erlotinib.
XL184 is a small molecule that simultaneously inhibits the MET, RET and
VEGFR receptor tyrosine kinases. In the initial phase 1 part of the study,
safety and pharmacokinetics of combining XL184 with erlotinib will be
evaluated. The primary endpoint of the phase 2 part of the study is overall
response rate. Secondary endpoints include progression-free survival,
overall survival and pharmacodynamics.
"XL184 is a potent inhibitor of MET, and MET amplification has been
shown to play an important role in the development of resistance to EGFR
inhibitors in NSCLC," said Michael Morrissey, Ph.D., president of research
and development of Exelixis. "Our preclinical data suggest that XL184
effectively inhibits growth of cancer cells that have become resistant to
EGFR inhibitors through activation of the MET signaling pathway. XL184 also
potently inhibits VEGFR, which is a validated target in the treatment of
NSCLC. The compound has shown encouraging anti-tumor activity in an initial
phase 1 trial and we are executing a phase 2 clinical development program,
and are planning on initiation of a pivotal trial for XL184 in medullary
thyroid cancer in 2008."
The phase 1/2 study of XL184 is expected to enroll up to 86 NSCLC
patients who have had disease progression while on erlotinib. The phase 1
portion of the study will evaluate dose escalation of XL184 in combination
with erlotinib, both administered daily. Patients in the first cohort will
receive a dose of XL184 that is below the maximum tolerated dose (MTD)
identified in the ongoing phase 1 trial of XL184, in combination with
erlotinib. Subsequent cohorts will receive erlotinib in combination with
escalating doses of XL184 until the MTD is reached. In the phase 2 portion
of the study, patients will be randomized to receive XL184 at the MTD alone
or in combination with erlotinib. Additionally, correlative studies will
evaluate MET amplification and EGFR mutational status. MET and EGFR
signaling activity will be assessed in tumor and surrogate tissue.
Data from an ongoing phase 1 trial of XL184 in patients with advanced
malignancies were presented in October 2007 at the 2007 AACR-NCI-EORTC
International Conference on Molecular Targets and Cancer Therapeutics
(Abstract #A152). Investigators reported that anti-tumor activity had been
observed in a variety of cancers at doses that are not associated with
significant toxicity. There were 33 patients available for safety,
pharmacokinetic and tumor response analyses as of the June 22, 2007 cutoff;
further data were also provided for six additional patients after the
cutoff. Of seven patients with medullary thyroid cancer (MTC), three had
partial responses (two confirmed and one unconfirmed) as of the date of the
AACR-NCI- EORTC Conference. In addition, as of such date, six of the seven
patients had tumor shrinkage and one had non-measurable disease. All seven
assessable patients with MTC experienced a rapid decrease in plasma levels
of calcitonin, a marker frequently elevated in MTC, and six of the seven
patients had a decrease in the tumor marker carcinoembryonic antigen. All
seven MTC patients remain on study. In addition, one patient with a
neuroendocrine tumor has an unconfirmed partial response. In total, 15
patients with various malignancies have had stable disease lasting from 3 -
20 months, including nine patients with stable disease for more than six
months.
To date, five dose-limiting toxicities (DLTs) have been reported,
including Grade 3 palmar/plantar erythema (hand-foot syndrome), Grade 3 AST
elevation, Grade 3 ALT elevation, and Grade 3 lipase elevation in patients
dosed at 11.52 mg/kg (intermittent dosing schedule), as well as a DLT of
Grade 2 mucositis in a patient dosed at 265 mg (daily dosing schedule).
Serious adverse events (AEs) considered possibly or probably related to
XL184 include one report each of Grade 3 fatigue and Grade 3 pulmonary
embolism. Dose escalation continues in order to determine a maximum
tolerated dose (MTD).
About XL184
XL184 is a novel, orally administered, small molecule anticancer
compound that in preclinical models has demonstrated potent inhibition of
both MET and VEGFR2. XL184 has also exhibited potent inhibition of other
important receptor tyrosine kinases (RTKs) that have been implicated in
various forms of cancer including RET, KIT, FLT3, and TIE2. In preclinical
efficacy studies, XL184 has inhibited tumor growth and induced the
regression of large tumors in a broad range of human tumor xenograft models
including breast cancer, lung cancer and glioma. In laboratory studies,
XL184 has demonstrated good oral bioavailability and pharmacokinetic
properties.
About Exelixis
Exelixis, Inc. is a development-stage biotechnology company dedicated
to the discovery and development of novel small molecule therapeutics for
the treatment of cancer and other serious diseases. The company is
leveraging its fully integrated drug discovery platform to fuel the growth
of its development pipeline, which is primarily focused on cancer.
Currently, Exelixis' broad product pipeline includes investigational
compounds in phase 2 and phase 1 clinical development for cancer and renal
disease. Exelixis has established strategic corporate alliances with major
pharmaceutical and biotechnology companies, including GlaxoSmithKline,
Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and
Daiichi-Sankyo. For more information, please visit the company's web site
at http://www.exelixis.com.
Forward-Looking Statements
This press release contains forward-looking statements, including,
without limitation, statements related to the future development and
potential efficacy of XL184, the future conduct of the phase 1/2 trial of
XL184 and the expected timing of the initiation of a pivotal trial of
XL184. Words such as "expected," "will," "planning", "suggest" and similar
expressions are intended to identify forward-looking statements. These
forward-looking statements are based upon Exelixis' current expectations.
Forward-looking statements involve risks and uncertainties. Exelixis'
actual results and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of these risks
and uncertainties, which include, without limitation, the lengthy, costly
and uncertain process of clinical testing of XL184 and the potential
failure of XL184 to demonstrate safety and efficacy in clinical testing.
These and other risk factors are discussed under "Risk Factors" and
elsewhere in Exelixis' quarterly report on Form 10-Q for the quarter ended
September 30, 2007 and Exelixis' other filings with the Securities and
Exchange Commission. Exelixis expressly disclaims any duty, obligation or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change in
Exelixis' expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Exelixis, Inc.
http://www.exelixis.com
Exelixis iniþiazã Faza 1 / 2 proces al XL184 la pacienþii cu Non-Small Cell Lung Cancer - Exelixis Initiates Phase 1/2 Trial Of XL184 In Patients With Non-Small Cell Lung Cancer - articole medicale engleza - startsanatate